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Introduction
Catecholamines, such as epinephrine and norepinephrine, regulate blood pressure via rapid and reversible effects on contraction of blood vessels by activating alpha adrenergic receptors in vascular smooth muscle cells (VSMC)' (1) . These effects are mediated mainly by alpha, adrenergic receptors (2) . Two major subtypes of alpha1 receptors (alphalA and alphalB) have been identified in pharmacological studies (3) (4) (5) . Among several criteria, alphalA receptors are insensitive to the irreversible alpha adrenergic antagonist chlorethylclonidine, whereas alphalB receptors are inactivated by chlorethylclonidine (2) . The cDNA encoding the alphalB adrenergic receptor from hamster DDT1MF2 cells has been cloned (6) . An additional subtype, termed the alphalc receptor, has been cloned from bovine brain; the pharmacological significance of this subtype is uncertain (7) . Subsequently, two groups cloned an additional subtype of alpha1 adrenergic receptors termed alphalA (8) or alphalD (9) ; the pharmacological properties of this receptor are similar but significantly different from those of the pharmacologically defined alphalA receptor. Consequently, it appears that the pharmacologically described alphalB receptor has been identified by molecular cloning, whereas the pharmacologically identified alphalA receptor has not been isolated yet by molecular biological techniques.
In addition to regulation of blood vessel contraction, catecholamines also have long-term trophic effects on the growth of arterial smooth muscle cells. Epinephrine and norepinephrine stimulate the proliferation of rat thoracic and bovine aortic smooth muscle cells in culture (10, 11) . Nakaki et al. (12) reported that norepinephrine stimulates DNA synthesis in quiescent cloned rat aortic smooth muscle cells. Prazosin, a selective alpha1 adrenergic receptor antagonist, reduces intimal hyperplasia in the rabbit abdominal aorta (13) . There is evidence suggesting that catecholamine receptors in vascular smooth muscle induce c-fos gene and stimulate cell growth (14) . By injecting adrenergic agonists into rats, Majesky et al. (14) showed that alpha1 adrenergic stimulation caused an increase in c-fos mRNA in rat aorta. c-fos is a protooncogene which likely plays an important role in cell growth; protooncogenes have been shown to be activated early during the development of smooth muscle cell hypertrophy (15) .
The purpose of this study was to investigate the potential expression and role of alpha1 adrenergic receptor subtypes in rat aorta and cultured rat aortic smooth muscle cells in inducing the expression of c-fos gene. It is not known which subtypes of alpha, adrenergic receptors are involved in the growth of smooth muscle cells. Using an in vitro preparation of rat aorta and cultured VSMC, we investigated and compared alpha1 adrenergic induction of c-fos mRNA.
Methods
Materials. Agarose, trypsin-EDTA (XIO), antibiotic antimycotic (x 100) including 10,000 U penicillin, 10,000 ug streptomycin, and 25 ,Og amphotericin B/ml, 1:1 mixture of DME and Ham's F12, L-glutamine, and RNase T2 were obtained from Gibco Laboratories (Grand Island, NY). Fetal Tissue preparation. Tissue preparation of rat aorta was performed as described by Hiremath et al. (16) . Briefly, thoracic aortas from male Sprague-Dawley rats (200-250 g) were dissected out, and fat and connective tissues were removed. The vessels were placed in KRB at 370C and were equilibrated for 60 min while bubbled with 95% 02/5% C02. Then, vessels were incubated with various drugs as described.
Cell culture. VSMC (medial layer) and fibroblasts (adventitia layer) were prepared in culture by enzyme digestion of aorta from male Sprague-Dawley rats (200-250 g) by modification of the procedure of Smith and Brock (17) . Cultured cells were maintained in a 1:1 mixture of DME and Ham's F12 (DME/F12), 10% heat-inactivated FCS, penicillin (100 U/ml), streptomycin (100 Ag/ml), amphotericin B (0.25 ttg/ml), 2 mM L-glutamine, and 15 mM Hepes. Cells were incubated at 370C in humidified atmosphere of 95% air/5% C02. The medium was changed every 3 d, and cells were passaged by 0.05% trypsin/ 0.02% EDTA solution. Studies were conducted on VSMC (passages 4-12) and fibroblasts (passages 3-8) that had achieved confluence in 10% FCS/DME/F12. Then, the cells were incubated in a defined serumfree medium (DME/F12 plus insulin [5 X 10-' MI, transferrin [ actin cDNA used as a hybridization probe (14). P-Actin mRNAs were unchanged by phenylephrine. Effects of adrenergic receptor antagonists on phenylephrineinduced c-fos mRNA in rat aorta are shown in Fig. 2, A (Fig. 3) . Phenylephrine caused increases in c-jun and c-myc mRNA which were both inhibited by prazosin (data not shown). Fold inductions of c-jun and cmyc mRNA from basal values were less than those which occurred for c-fos mRNA.
To examine the second messenger systems involved in these effects of alpha1 receptors on expression of c-fos mRNA, we Effects of adrenergic receptor antagonists on phenylephrineinduced c-fos mRNA in rat VSMC are shown in Fig. 6 , A and B. In VSMC, induction of c-fos mRNA by phenylephrine ( 10-5 M) was abolished by prazosin (10-6 M), while propranolol (10-5 M) did not inhibit the induction by phenylephrine (data not shown), similar to what was seen previously in rat aorta. These results suggest that induction of c-fos mRNA by phenylephrine is mediated through alpha, adrenergic receptors. Cultured cells were incubated with CEC for 30 min, were washed with DME/F12 medium four times, and were equilibrated for 30 min in medium before the stimulation of phenylephrine. CEC blocked phenylephrine-induced c-fos mRNA completely. This result indicates that phenylephrine-induced c-fos mRNA is mediated by CEC-sensitive alpha, adrenergic receptors in VSMC as well as in rat aorta.
We compared increases in c-fos mRNA values induced by phenylephrine and angiotensin II in Fig. 7, A and B . In aorta, induction of c-fos mRNA by phenylephrine was much greater than that mediated by angiotensin II. On the other hand, in VSMC the effect of angiotensin H (10-6 M) on expression of c-fos mRNA was much greater than that of phenylephrine (10-5 M) , the opposite of the result found in intact rat aorta incubated in vitro with these agonists.
We prepared adventitia fibroblasts in culture from the outer layer of aorta and investigated effects of adrenergic agents on c-fos mRNA using these cells. In adventitia fibroblasts, beta adrenergic stimulation induced c-fos mRNA, whereas alpha, adrenergic stimulation had little effect (data not shown).
Because aortic tissue represents a heterogeneous cell population, in situ hybridization analysis was performed to directly demonstrate localization of c-fos mRNA (Fig. 8) . Emulsion autoradiography sections demonstrated that basal expression of c-fos mRNA was low and that increased expression after activation with phenylephrine was seen primarily in the medial smooth muscle layer rather than in the adventitial fibroblast layer. Only a few grains were visible over sections of aorta which were hybridized to the sense probe, suggesting low nonspecific binding.
Using an RNase protection assay, we detected alphalAD adrenergic receptor mRNA as Lomasney et al. (8) did previously using Northern blotting (Fig. 9 ). In addition, we detected alphalB adrenergic receptor mRNA as well which had not been detected previously in Northern blotting experiments. These RNase protection experiments were not designed to compare the relative expression of these subtypes in rat aorta.
Discussion
This study demonstrates that in intact rat aorta incubated in vitro and in cultured rat VSMC, phenylephrine induces a rapid and transient increase in c-fos mRNA which is blocked by prazosin. The increase in c-fos mRNA induced by phenylephrine was also blocked by chlorethylclonidine. The protein kinase C inhibitor H-7 and L-type Ca2" channel antagonist nifedipine each partially inhibited phenylephrine-induced c-fos mRNA expression. The relative response to activation of alpha, adrenergic receptors versus angiotensin II receptors was much greater in aorta compared with cultured VSMC.
While it is well known that the sympathetic nervous system has marked effects on blood vessel contraction, autonomic nerves also have trophic effects on arterial smooth muscle mass (1, (24) (25) (26) . Catecholamines stimulate the growth of arterial smooth muscle cells in vitro (27 (28, 29) . It has been suggested that the cfos gene, which is induced by platelet-derived growth factor, angiotensin II, and endothelin, has an important influence on the growth of vascular smooth muscle (30) (31) (32) (33) .
Studies of alpha1 adrenergic receptor-mediated contraction of various smooth muscles reveal evidence for subtypes of alpha1 adrenergic receptors. Minneman et al. (4) showed, in studies examining several rat tissues, the proportion of alpha1 adrenergic receptor-binding sites inactivated by chlorethylclonidine correlated with the sites having a low affinity for WB4IO1.
They proposed the existence of two alpha1 adrenergic receptor subtypes, which were termed alphalA (chlorethylclonidine-insensitive) and alphalB (chlorethylclonidine-sensitive) (4 (34) . The molecular cloning of several alpha, adrenergic receptor subtypes has been reported (6-9). The alphal adrenergic receptor expressed in DDT1MF2 cells was the first subtype cloned and has the expected properties of an alphalB adrenergic receptor described pharmacologically (6) . An alpha, adrenergic receptor cDNA isolated from a bovine brain which does not have the characteristics of an alphalA or alphalB receptor subtype has been termed the alphaic subtype (7). Subsequently, two groups cloned additional alpha, adrenergic cDNAs from brain which have similar properties to that of the pharmacologically described alphalA subtype, but not exactly (8, 9) . These cDNAs are identical except for two codons and are likely the same receptor subtype which has been recently termed the alphalA, D receptor (35) although no consistent terminology has been settled.
To investigate which subtypes of alpha, adrenergic receptors mediate induction of c-fos mRNA, we used CEC, which selectively and irreversibly inactivates alphalB receptors in pharmacological experiments. In addition, CEC may at least partially block cloned and expressed alphalAD receptors (8, 9) . Alphaic receptors may be partially resistant to CEC (7) . In other words, CEC fully inactivates alphalB receptors and partially blocks the cloned alphalAD and alphalc receptors; on the other hand, CEC spares the pharmacologically defined alphalA receptor which may not have yet been cloned. We found that CEC completely blocked phenylephrine-induced c-fos mRNA accumulation.
This result suggests that in rat aorta induction of c-fos mRNA was mediated by alphalB adrenergic receptors or possibly also alphalAD receptors. These results also suggest that the pharmacologically defined CEC-insensitive alphalA receptor does not regulate expression of c-fos mRNA in rat aorta. In rat tissues, the major alpha1 subtypes are alphalA and alphalB defined pharmacologically (34) . Experiments measuring catecholamine-induced contraction of rat aorta based on sensitivity to CEC suggest that alphalB adrenergic receptors are the subtype predominantly mediating contraction in this vessel (36) . However, norepinephrine-induced contraction of rat aorta is also inhibited by WB4101, a putative selective alphalA adrenergic receptor antagonist (36) . Thus, subclassification of alphalA and alphalB adrenergic receptors in rat aorta in terms of contractile responses by potentially selective compounds is uncertain.
Lomasney et al. (8) used both alphalB and alphalAD adrenergic receptor cDNA probes to investigate expression of these subtypes in rat aorta using Northern blot analysis and detected only alphalAD adrenergic receptor mRNA. However, as indicated above, functional studies in rat aorta have demonstrated that the selective irreversible alphalB adrenergic receptor antagonist CEC markedly inhibits the contraction induced by the stimulation of alpha, adrenergic receptors in rat aorta (36, 37) , suggesting that alphalB adrenergic receptors are expressed in rat aorta. Indeed, we have found in the current study using an RNase protection assay that both alphalB and alphalAD mRNAs are expressed in rat aorta. As RNase protection assays are generally more sensitive and specific than Northern blot analysis, those data provide strong evidence for expression of both these receptor subtypes in rat aorta. We also found faint alphaic recep- ( 10-5 M) . Nonstimulated aorta (left panels) and stimulated aorta with phenylephrine (middle panels) were fixed and OCT-embedded, and sections were hybridized using a 35S-labeled antisense RNA probe specific for rat c-fos as described in Methods. To evaluate nonspecific background, aorta stimulated with phenylephrine was hybridized using a 35S-labeled sense RNA probe specific for rat c-fos (right panels). After RNase digestion and washing, sections underwent emulsion autoradiography, were counterstained with hematoxylin and eosin, and visualized with dark-field microscopy (upper panels) or with bright-field microscopy (lower panels). In all photographs, endothelial layers are to the left-hand side. Data are representative of three separate experiments. x400. tor mRNA signals in aorta, suggesting the possibility of low levels of expression of that subtype in aorta as well (data not shown).
Efforts have been extended to link the various alpha, receptor subtypes to specific signal transduction mechanisms. Activation of alphalA adrenergic receptors have been found to promote the influx of extracellular Ca2" via L-type Ca2" channels (38) . In contrast, alphalB and alphalc adrenergic receptors are linked to stimulation of phospholipid hydrolysis which produces two second messengers, diacylglycerol, which activates protein kinase C, and inositol 1,4,5-triphosphate, which acts on a specific intracellular receptor to release sequestered Ca2+ (35, 38) . Recently, it has been shown that cloned and expressed alphalAD adrenergic receptors activate influx of extracellular Ca2+ through L-type Ca2+ channels (35) . However, it is difficult and in any case premature to classify the alpha adrenergic receptor subtypes on the basis of their potential signaling mechanisms. Inhibition of phenylephrine-induced c-fos accumulation by the two protein kinase C inhibitors H-7 and bisindolylmaleimide GF 109203X (39) in rat aorta suggests that CEC-sensitive alpha, adrenergic receptors are coupled to stimulation of phospholipid hydrolysis, and activation of protein kinase C plays an important role in induction of c-fos mRNA. Furthermore, we have found that nifedipine also inhibits phenylephrine-induced c-fos mRNA accumulation. This result suggest that c-fos mRNA induced by phenylephrine is also dependent on the influx of extracellular Ca2". The (42) found that nifedipine and H-7 independently partially inhibited phenylephrine-induced contraction in rat aorta, whereas both compounds together almost completely inhibited contraction. Interestingly, induction of c-fos mRNA by angiotensin II in cultured rat aortic smooth muscle cells is dependent on both a rise in intracellular Ca 2+ concentration and activation of protein kinase C (32). -1 90bp
f-actin-9 -1 70bp Figure 9 . RNase protection assays of rat alphalAD and alpha15 adrenergic receptor mRNA in rat aorta. 50 ug of total RNA isolated from rat thoracic aorta (aorta RNA) or 10 jg of control transfer RNA (tRNA) was hybridized with RNA probes of alphalAD adrenergic receptor (AR) and fi-actin (lanes I and 3) or probes for alphalB adrenergic receptor and /3-actin (lanes 2 and 4). After RNase digestion, RNase-resistant hybrids were run on a 6% polyacrylamide/8 M urea gel. Probes in the presence of tRNA were digested completely by RNase (tRNA lanes). In cultured smooth muscle cells, angiotensin II is known to be a strong inducer on c-fos mRNA accumulation and to be involved in vascular hypertrophy (15, 33) . We compared the effect of phenylephrine on c-fos mRNA with that of angiotensin II both in rat isolated aorta and in cultured smooth muscle cells. In cultured VSMC, angiotensin II had a very large effect on induction of c-fos mRNA, much greater than seen with phenylephrine. In contrast, in rat aorta freshly isolated in vitro, the effect of phenylephrine was much greater than that of angiotensin II. The hypertrophic effect of angiotensin II in vitro is associated with the activation of protooncogenes such as c-fos, c-jun, and c-myc (43) . We have shown that phenylephrine induces cjun mRNA and c-myc mRNA as well as c-fos mRNA in rat aorta. This result suggests the possibility that adrenergic stimulation plays a very important role in vascular hypertrophy in intact aorta. Clearly, culturing of smooth muscle cells leads to changes in the responses to these agonists, which could be misleading if simply extrapolated back to the expected responses in intact vessels. The explanation for this change in culture is uncertain, and whether it relates to change in expression of alpha, adrenergic receptor subtypes or some other mechanism requires further investigation.
Rat aorta contains adventitia fibroblasts as well as smooth muscle. Results of the in situ hybridization experiments suggest that in rat aorta induction of c-fos mRNA via alpha, adrenergic receptors occurred primarily in the smooth muscle layer, which is consistent with the results in cultured VSMC and adventitia fibroblasts. These results suggest that in the intact rat aorta alpha, adrenergic stimulation of c-fos mRNA is due to response in medial smooth muscle and support the use of isolated rings of aorta as a useful model system to investigate growth-promoting effects of catecholamines.
Our results suggest that rat aorta expresses at least two alpha, adrenergic receptor subtypes (alphaIAD and alphalB) and that these are potentially involved in inducing expression of cfos gene in vascular smooth muscle. The signaling pathways involved in mediating these responses are complex, involving both Ca2" influx and activation of protein kinase C. Isolated rings of aorta provide a useful model in the study of growthpromoting effects induced by catecholamines and may be particularly useful identifying novel pharmacological antagonists of these receptors.
